Abstract
The spread of cancer cells from the primary tumor to a distant site involves many of the invasive processes normally required for wound healing, including migration through the local connective tissue, invasion of the vasculature, extravasation, invasion of the connective tissue at a distant site, and angiogenesis. Thus, the abilities of tumor cells to invade the host, and to induce endothelial cell invasion and neovascularization, are central to malignant progression. The plasminogen activator system, which plays a direct role in stimulating α5β1 integrin fibronectin receptor-mediated invasion during wound healing, is also very important in tumor cell invasion and metastasis, as well as in angiogenesis. Therefore, the α5β1 receptor and the plasminogen activator system may be promising targets for directed anticancer therapies.
Keywords: fibronectin, invasion, integrins, urokinase, metastasis
Current Cancer Drug Targets
Title: Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Volume: 5 Issue: 7
Author(s): Donna L. Livant
Affiliation:
Keywords: fibronectin, invasion, integrins, urokinase, metastasis
Abstract: The spread of cancer cells from the primary tumor to a distant site involves many of the invasive processes normally required for wound healing, including migration through the local connective tissue, invasion of the vasculature, extravasation, invasion of the connective tissue at a distant site, and angiogenesis. Thus, the abilities of tumor cells to invade the host, and to induce endothelial cell invasion and neovascularization, are central to malignant progression. The plasminogen activator system, which plays a direct role in stimulating α5β1 integrin fibronectin receptor-mediated invasion during wound healing, is also very important in tumor cell invasion and metastasis, as well as in angiogenesis. Therefore, the α5β1 receptor and the plasminogen activator system may be promising targets for directed anticancer therapies.
Export Options
About this article
Cite this article as:
Livant L. Donna, Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer, Current Cancer Drug Targets 2005; 5 (7) . https://dx.doi.org/10.2174/156800905774574002
DOI https://dx.doi.org/10.2174/156800905774574002 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Review of Small Molecule Ret Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry High-Intensity Focused Ultrasound in the Treatment of Breast Cancer
Current Medicinal Chemistry Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Chemopreventive and Anti-leukemic Effects of Ethanol Extracts of Moringa oleifera Leaves on Wistar Rats Bearing Benzene Induced Leukemia
Current Pharmaceutical Biotechnology Disulfiram, and Disulfiram Derivatives as Novel Potential Anticancer Drugs Targeting the Ubiquitin Proteasome System in Both Preclinical and Clinical Studies
Current Cancer Drug Targets Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Protein-Based HIV-1 Microbicides
Current HIV Research Neurological Complications of Anderson-Fabry Disease
Current Pharmaceutical Design Peptides in Melanoma Therapy
Current Pharmaceutical Design Inhibiting the Enzymes of the Endothelin and Renin-Angiotensin Systems in Cancer
Current Enzyme Inhibition Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways
Anti-Cancer Agents in Medicinal Chemistry Progress in the Discovery of Polo-like Kinase Inhibitors
Current Topics in Medicinal Chemistry Developing FGFR4 Inhibitors As Potential Anti-Cancer Agents Via In Silico Design, Supported by In Vitro and Cell-Based Testing
Current Medicinal Chemistry Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Lymphangiogenesis and Anti-Tumor Immune Responses
Current Molecular Medicine Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets